Cel-Sci claims treatment with Multikine led to a statistically significant reduction in cholesterol, but what was their drug compared to for that conclusion to be reached? None of the phase II studies of Multikine conducted by Cel-Sci included a control arm -- meaning all the patients received Multikine. How then, can these studies demonstrate a statistically significant reduction in cholesterol? Cel-Sci doesn't say.
Perhaps Cel-Sci split the Multikine-treated patients into two groups -- those taking statin drugs for high cholesterol and those who were not. Again, Cel-Sci doesn't explain. Of course, it doesn't really matter because we run full circle back to the data-mining problem -- the studies weren't originally designed to split patients into statin and non-statin users.
If the cholesterol-lowering finding from this meta-analysis of Multikine studies is reality challenged, why would Cel-Sci bother with it? The answer goes back to what I warned up top -- positive results derived from post-hoc data mining are usually a smokescreen seeking to cover up other problems.
In Cel-Sci's case that means problems with the ongoing phase III study of Multikine, which is taking forever to get off the ground. The number of press releases issued by Cel-Sci announcing the start of the phase III trial appears to exceed the number of patients actually enrolled. Cel-Sci's problems run deeper still because lackluster Multikine data from the phase II studies gives the drug little chance of succeeding in the phase III study.Yet Cel-Sci's needs to keep hope alive, lest gullible retail shareholders lose interest and the disbursement of management's annual paychecks become threatened. Desperate companies like Apricus and Cel-Sci use data dredging as a necessary survival tool. Smart investors recognize the danger signs and steer clear. Post script: As I was putting this column together, I saw news that Transdel Pharmaceuticals (TDLP) filed for bankruptcy this week and sold off its remaining assets. Transdel was also a data-mining offender. Fair warning. More companies guilty of data-mining: Osiris Therapeutics (OSIR), Agenus (AGEN) (formerly Antigenics), Introgen Therapeutics (defunct, another bankruptcy), and Cell Therapeutics (CTIC), which famously re-analyzed a failed lung cancer trial claiming its drug Opaxio (formerly Xyotax) only worked for women.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV